| Name | Title | Contact Details |
|---|
Emerge Clinical Decision Solutions, a leader in the cardiology technology world, engineers software developed by leading cardiologists to help medical providers and administrators improve care. The software leverages a patented algorithm to analyze more than 8,000 unique data points in seconds and help alert doctors of any missed information, suggest specific tests and outline appropriate care paths. By helping doctors pinpoint conditions that are traditionally more difficult to diagnose, Emerge is helping patients receive the right care at the right time before costly, stressful emergency visits become necessary. The software has been proven to increase identification of certain cardiac diseases by as much as 300 percent.
Founded in 1978 as Immunological Associates of Denver, now known as LABS, Inc., LABS operates laboratories in Centennial, Colorado and Philadelphia, Pennsylvania. Each facility is independently certified, accredited, licensed or registered by numerous agencies that may include AABB, American Society of Histocompatibility and Immunogenetics (ASHI), the College of American Pathologists (CAP), Clinical Laboratory Improvement Amendments (CLIA), the U.S. Food and Drug Administration (FDA), International Organization of Standardization (ISO) and the states of California, Florida, Maryland, New York, Rhode Island and West Virginia.
OPS is a Grand Prairie, TX-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Diadexus is a diagnostics company developing and commercializing products that aid in the prediction of cardiac disease risk, providing healthcare providers with actionable information for managing patients. We pioneered the testing of Lp-PLA2 (lipoprotein-associated phospholipase A2), a marker of vascular-specific inflammation that provides new information, over and above traditional risk factors measured in a lipid panel, and has over a decade of peer-reviewed literature validating this biomarker`s utility. Our products are the only two FDA-cleared tests to measure Lp-PLA2: The PLAC® Test ELISA Kit first cleared by the FDA in 2003 and The PLAC® Test for Lp-PLA2 Activity cleared in December 2014. Our pipeline of advanced cardiac biomarkers includes biomarkers for heart failure, proADM, proET-1 and proANP. Each marker gives distinct, additive information for healthcare providers over currently available markers. Diadexus also provides services to pharmaceutical partners to address the need to incorporate biomarkers in clinical development. Our portfolio of advanced cardiac biomarkers is available to be paired with novel therapeutics in development for indications where cardiovascular risk information would provide valuable insights. This information can be used by pharmaceutical companies in targeting the appropriate patient population and understanding the potential long-term side effects for their therapeutics, potentially avoiding long-term follow up studies.
Moss Landing Marine Labs is a Moss Landing, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.